{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:25:27Z","timestamp":1764739527363,"version":"3.46.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Weifang Science and Technology Development Program","award":["2025YX098"],"award-info":[{"award-number":["2025YX098"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J01718"],"award-info":[{"award-number":["2022J01718"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of Guillain-Barr\u00e9 syndrome (GBS) during bortezomib treatment for multiple myeloma (MM) is rare. Clinical vigilance regarding this serious adverse event is imperative for timely diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of the hospital\u2019s health information system (HIS) and report three cases of GBS that occurred during bortezomib-based treatment in patients with MM. A retrospective analysis of the patients\u2019 clinical presentations, diagnostic processes, treatments, and prognoses was conducted. Additionally, a literature search was performed by using the keywords \u201cmultiple myeloma,\u201d \u201cbortezomib,\u201d \u201cGBS,\u201d and \u201cpolyneuropathy\u201d in the PubMed and China National Knowledge Infrastructure (CNKI) databases, which yielded 30 relevant published cases for review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33 cases were included in the analysis. The VRD regimen (bortezomib, lenalidomide, and dexamethasone) appeared to be associated with the development of GBS in patients with IgA-type MM, whereas the VTD regimen (bortezomib, thalidomide, and dexamethasone) was more commonly associated with IgG-type MM. Intravenous immunoglobulin (IVIG) and plasma exchange represented the main first-line treatments, and most of the patients achieved varying degrees of neurological recovery within a median of 4.5\u202fmonths (range: 3\u202fweeks to 21\u202fmonths).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neurological examination, cerebrospinal fluid analysis revealing albuminocytologic dissociation, and nerve conduction studies were helpful for diagnosing GBS. Prompt treatment with IVIG and\/or plasma exchange can significantly improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1641892","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:27Z","timestamp":1764739227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical analysis of the development of Guillain-Barr\u00e9 syndrome during bortezomib treatment for multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing-Gang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Ji","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.14715\/cmb\/2024.70.6.25","article-title":"The efficacy of bortezomib-based regimens on survival state in newly diagnosed multiple myeloma patients","volume":"70","author":"Muhamedamin Hasan","year":"2024","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CND.0000000000000077","article-title":"Bortezomib-associated demyelinating neuropathy--clinical and pathologic features","volume":"16","author":"Thawani","year":"2015","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/0284186X.2020.1723163","article-title":"Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity","volume":"59","author":"Gendreau","year":"2020","journal-title":"Acta Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"104353","DOI":"10.1016\/j.critrevonc.2024.104353","article-title":"Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach","volume":"197","author":"Yang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"001","DOI":"10.29328\/journal.apcr.1001028","article-title":"Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma","volume":"6","author":"Koeppen","year":"2022","journal-title":"Arch Pathol Clin Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1529-8027.2010.00287.x","article-title":"Bortezomib-induced inflammatory neuropathy","volume":"15","author":"Saifee","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e1220","DOI":"10.1212\/WNL.0000000000006246","article-title":"Surgery and risk of Guillain-Barr\u00e9 syndrome: a French nationwide epidemiologic study","volume":"91","author":"Rudant","year":"2018","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-025-04045-3","article-title":"Guillain-Barr\u00e9 syndrome in patients with multiple myeloma: three cases report and literature review","volume":"25","author":"Li","year":"2025","journal-title":"BMC Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.53394\/akd.981986","article-title":"Guillain Barr\u00e9 syndrome in a multiple myeloma patient after the autologous transplantation: a case report","volume":"7","author":"Seyhanl\u0131","year":"2021","journal-title":"Akd Med J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/10428190701760003","article-title":"Guillain-Barr\u00e9 syndrome after transplantation","volume":"49","author":"Zhang","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/011871529X352283250305042317","article-title":"Diagnostic challenges of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome: a rare case report and review of the literature","volume":"25","author":"Kumar","year":"2025","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ana.26965","article-title":"Amyloid neuropathy: from pathophysiology to treatment in light-chain amyloidosis and hereditary transthyretin amyloidosis","volume":"96","author":"Chompoopong","year":"2024","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"707134","DOI":"10.3389\/fneur.2021.707134","article-title":"Light-chain amyloidosis with peripheral neuropathy as an initial presentation","volume":"12","author":"Qian","year":"2021","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2162-3619-1-20","article-title":"Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy","volume":"1","author":"Jeter","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"JCO.20.01399","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1641892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:27Z","timestamp":1764739227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1641892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":18,"alternative-id":["10.3389\/fneur.2025.1641892"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1641892","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1641892"}}